Title:
APPLICATION OF RBM46 AS TESTICULAR TUMOR MARKER
Document Type and Number:
WIPO Patent Application WO/2021/000673
Kind Code:
A1
Abstract:
Disclosed by the present application is an application of Rbm46 as a testicular tumor marker. Disclosed is an application of a quantitative detection agent for Rbm46 mRNA or protein in the preparation of a reagent or kit used for the diagnosis and/or prognosis evaluation of a testicular tumor; reduced expression of Rbm46 mRNA or protein is an indication of a testicular tumor and/or an indication of poor prognosis of a testicular tumor. The measurement of Rbm46 mRNA or protein may be used for the detection or diagnosis of testicular tumors, or the evaluation and monitoring of patient prognosis, and has an important clinical application value.
Inventors:
LIU NIAN (CN)
Application Number:
PCT/CN2020/093005
Publication Date:
January 07, 2021
Filing Date:
May 28, 2020
Export Citation:
Assignee:
BEIJING TAIDONG BIOTECHNOLOGY CO LTD (CN)
International Classes:
C12Q1/6886; C12N15/11
Domestic Patent References:
| WO2017203526A1 | 2017-11-30 |
Foreign References:
| CN110195109A | 2019-09-03 |
Other References:
WAN, SHENGKAI ET AL: "National Academy of Clinical Biochemistry NACB Practice Guidelines: Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers", CHINESE JOURNAL OF CLINICAL LABORATORY SCIENCE, vol. 30, no. 2,, 28 February 2012 (2012-02-28)
Attorney, Agent or Firm:
CHOFN INTELLECTUAL PROPERTY (CN)
Download PDF: